| Disease ID | Disease name | Source of annotation with TGFB1 | OMIM link | Number of associated genes | genes |
|---|---|---|---|---|---|
| 219700 | CYSTIC FIBROSIS | ClinVar, OMIM | link to OMIM | 3 | TGFB1, FCGR2A, CFTR |
| 131300 | CAMURATI-ENGELMANN DISEASE | ClinVar, OMIM, HUMSAVAR | link to OMIM | 1 | TGFB1 |
Download the gene annotation in CSV format
| KEGG pathway | KEGG ID | KEGG IC |
|---|---|---|
| Pancreatic cancer | hsa05212 | 6.56 |
| Colorectal cancer | hsa05210 | 6.52 |
| Renal cell carcinoma | hsa05211 | 6.6 |
| Intestinal immune network for IgA production | hsa04672 | 6.79 |
| Endocytosis | hsa04144 | 4.92 |
| FoxO signaling pathway | hsa04068 | 5.63 |
| Osteoclast differentiation | hsa04380 | 5.64 |
| Hypertrophic cardiomyopathy (HCM) | hsa05410 | 6.21 |
| Dilated cardiomyopathy | hsa05414 | 6.08 |
| Cytokine-cytokine receptor interaction | hsa04060 | 4.67 |
| Chagas disease (American trypanosomiasis) | hsa05142 | 5.99 |
| Leishmaniasis | hsa05140 | 6.32 |
| Amoebiasis | hsa05146 | 5.82 |
| Malaria | hsa05144 | 7.15 |
| Toxoplasmosis | hsa05145 | 5.71 |
| HTLV-I infection | hsa05166 | 4.59 |
| Hepatitis B | hsa05161 | 5.52 |
| TGF-beta signaling pathway | hsa04350 | 6.41 |
| Proteoglycans in cancer | hsa05205 | 5.02 |
| Rheumatoid arthritis | hsa05323 | 6.05 |
| Cell cycle | hsa04110 | 5.68 |
| Inflammatory bowel disease (IBD) | hsa05321 | 6.43 |
| Pathways in cancer | hsa05200 | 3.98 |
| Hippo signaling pathway | hsa04390 | 5.37 |
| Chronic myeloid leukemia | hsa05220 | 6.48 |
| Non-alcoholic fatty liver disease (NAFLD) | hsa04932 | 5.51 |
| MAPK signaling pathway | hsa04010 | 4.63 |
| Tuberculosis | hsa05152 | 5.17 |
| REACTOME pathway | REACTOME ID | REACTOME IC |
|---|---|---|
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 10.18 |
| Platelet degranulation | R-HSA-114608 | 6.68 |
| Host Interactions with Influenza Factors | R-HSA-168253 | 10.66 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.7 |
| Influenza Infection | R-HSA-168254 | 5.86 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 10.18 |
| Extracellular matrix organization | R-HSA-1474244 | 4.91 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.73 |
| Developmental Biology | R-HSA-1266738 | 3.48 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 10.98 |
| Elastic fibre formation | R-HSA-1566948 | 7.49 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.15 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.59 |
| ECM proteoglycans | R-HSA-3000178 | 6.75 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 10.18 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 10.98 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 10.18 |
| Syndecan interactions | R-HSA-3000170 | 8.23 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 7.1 |
| Infectious disease | R-HSA-5663205 | 4.47 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 10.4 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 9.98 |
| Diseases of signal transduction | R-HSA-5663202 | 4.89 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.81 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 8.98 |
| Disease | R-HSA-1643685 | 3.33 |
| TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 11.98 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 10.98 |
| Influenza Virus Induced Apoptosis | R-HSA-168277 | 11.98 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.98 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 8.28 |
| Hemostasis | R-HSA-109582 | 3.98 |
| Signal Transduction | R-HSA-162582 | 1.78 |
| GO term | GO ID | GO IC |
|---|---|---|
| cytokine receptor binding | GO:0005126 | 4.14 |
| cytokine activity | GO:0005125 | 4.34 |
| antigen binding | GO:0003823 | 5.02 |
| transforming growth factor beta receptor binding | GO:0005160 | 5.81 |
| kinase activator activity | GO:0019209 | 5.58 |
| enzyme binding | GO:0019899 | 2.27 |
| binding | GO:0005488 | 0.18 |
| molecular function regulator | GO:0098772 | 2.51 |
| kinase regulator activity | GO:0019207 | 4.5 |
| glycoprotein binding | GO:0001948 | 5.11 |
| growth factor activity | GO:0008083 | 4.66 |
| protein dimerization activity | GO:0046983 | 2.72 |
| type II transforming growth factor beta receptor binding | GO:0005114 | 7.79 |
| identical protein binding | GO:0042802 | 2.63 |
| protein homodimerization activity | GO:0042803 | 3.16 |
| protein kinase regulator activity | GO:0019887 | 4.6 |
| enzyme regulator activity | GO:0030234 | 2.85 |
| type III transforming growth factor beta receptor binding | GO:0034714 | 8.35 |
| type I transforming growth factor beta receptor binding | GO:0034713 | 7.44 |
| protein kinase activator activity | GO:0030295 | 5.68 |
| protein serine/threonine kinase activator activity | GO:0043539 | 6.91 |
| protein N-terminus binding | GO:0047485 | 5.11 |
| carbohydrate derivative binding | GO:0097367 | 2.03 |
| protein binding | GO:0005515 | 0.46 |
| receptor binding | GO:0005102 | 2.43 |
| protein heterodimerization activity | GO:0046982 | 3.64 |
| enzyme activator activity | GO:0008047 | 3.56 |